Stewart CF - Search Results

1

Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.

Gajjar A, Stewart CF, Ellison DW, Kaste S, Kun LE, Packer RJ, Goldman S, Chintagumpala M, Wallace D, Takebe N, Boyett JM, Gilbertson RJ, Curran T. Gajjar A, et al. Among authors: stewart cf. Clin Cancer Res. 2013 Nov 15;19(22):6305-12. doi: 10.1158/1078-0432.CCR-13-1425. Epub 2013 Sep 27. Clin Cancer Res. 2013. PMID: 24077351 Free PMC article. Clinical Trial.

2

Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity.

Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB. Stewart CF, et al. J Clin Oncol. 1994 Sep;12(9):1946-54. doi: 10.1200/JCO.1994.12.9.1946. J Clin Oncol. 1994. PMID: 8083716 Clinical Trial.

3

Phase I study of topotecan for pediatric patients with malignant solid tumors.

Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT, et al. Pratt CB, et al. J Clin Oncol. 1994 Mar;12(3):539-43. doi: 10.1200/JCO.1994.12.3.539. J Clin Oncol. 1994. PMID: 8120551 Clinical Trial.

4

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF. Baker SD, et al. Among authors: stewart cf. Cancer Chemother Pharmacol. 1996;37(3):195-202. doi: 10.1007/BF00688317. Cancer Chemother Pharmacol. 1996. PMID: 8529278

5

Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.

Furman WL, Baker SD, Pratt CB, Rivera GK, Evans WE, Stewart CF. Furman WL, et al. Among authors: stewart cf. J Clin Oncol. 1996 May;14(5):1504-11. doi: 10.1200/JCO.1996.14.5.1504. J Clin Oncol. 1996. PMID: 8622064 Clinical Trial.

6

Topoisomerase I interactive drugs in children with cancer.

Stewart CF, Zamboni WC, Crom WR, Gajjar A, Heideman RL, Furman WL, Meyer WH, Houghton PJ, Pratt CB. Stewart CF, et al. Invest New Drugs. 1996;14(1):37-47. doi: 10.1007/BF00173681. Invest New Drugs. 1996. PMID: 8880392 Review.

7

Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.

Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, Dryer ZA, Kurtzberg J, Bell B, Grier H, Vietti TJ. Tubergen DG, et al. Among authors: stewart cf. J Pediatr Hematol Oncol. 1996 Nov;18(4):352-61. doi: 10.1097/00043426-199611000-00004. J Pediatr Hematol Oncol. 1996. PMID: 8888741 Clinical Trial.

8

Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.

Zamboni WC, Houghton PJ, Thompson J, Cheshire PJ, Hanna SK, Richmond LB, Lou X, Stewart CF. Zamboni WC, et al. Among authors: stewart cf. Clin Cancer Res. 1998 Feb;4(2):455-62. Clin Cancer Res. 1998. PMID: 9516936

9

Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.

Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna SK, Luo X, Poquette C, McGovren JP, Houghton JA, Houghton PJ. Zamboni WC, et al. Among authors: stewart cf. Clin Cancer Res. 1998 Mar;4(3):743-53. Clin Cancer Res. 1998. PMID: 9533544

10

Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.

Zamboni WC, Gajjar AJ, Heideman RL, Beijnen JH, Rosing H, Houghton PJ, Stewart CF. Zamboni WC, et al. Among authors: stewart cf. Clin Cancer Res. 1998 Mar;4(3):783-9. Clin Cancer Res. 1998. PMID: 9533548

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

326 results

Search Page

Filters